Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning

I. Dorigatti (), C. A. Donnelly, D. J. Laydon, R. Small, N. Jackson, L. Coudeville and N. M. Ferguson
Additional contact information
I. Dorigatti: Imperial College London
C. A. Donnelly: Imperial College London
D. J. Laydon: Imperial College London
R. Small: Sanofi Pasteur
N. Jackson: Sanofi Pasteur
L. Coudeville: Sanofi Pasteur
N. M. Ferguson: Imperial College London

Nature Communications, 2018, vol. 9, issue 1, 1-9

Abstract: Abstract CYD-TDV is the first licensed dengue vaccine for individuals 9–45 (or 60) years of age. Using 12% of the subjects enroled in phase-2b and phase-3 trials for which baseline serostatus was measured, the vaccine-induced protection against virologically confirmed dengue during active surveillance (0–25 months) was found to vary with prior exposure to dengue. Because age and dengue exposure are highly correlated in endemic settings, refined insight into how efficacy varies by serostatus and age is essential to understand the increased risk of hospitalisation observed among vaccinated individuals during the long-term follow-up and to develop safe and effective vaccination strategies. Here we apply machine learning to impute the baseline serostatus for subjects with post-dose 3 titres but missing baseline serostatus. We find evidence for age dependence in efficacy independent of serostatus and estimate that among 9–16 year olds, CYD-TDV is protective against serotypes 1, 3 and 4 regardless of baseline serostatus.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-06006-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-06006-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-06006-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().